To the Editor: Hereditary nonpolyposis colorectal cancer, the most common cancer syndrome, accounts for 1 -6 % of colorectal cancer (1) . On the basis of Finnish mutation screening data, we have estimated that the population attributable fraction (PAF) of hereditary nonpolyposis colorectal cancer (HNPCC) was 2.2 % (2) . PAF, the proportion of the disease occurrence explained by the gene variant under study, is a useful measure in the estimation of the population impact of cancer susceptibility genes, particularly in the present era of ooding genomic data emanating from genome-wide association (GWA) scans. PAF helps to put the ndings on lowpenetrance genes in perspective with the previously established high-risk genes, thus providing a tool for genomic landscaping, as described elsewhere (3) . Familial risk conferred by the disease variant may also be a useful measure because eventually the disease variants have to explain the empirical familial risk, which for colorectal cancer in siblings is about 2.5 (4) . However, as most new variants are markers of rarer functional variants, the calculated familial risks would be underestimates (5) .
Here we calculate PAFs for the six recently described and veri ed susceptibility loci for colorectal cancer (6, 7) . e populations in these studies were European with a large British component. Tomlinson et al . (6) described ve loci with allelic odds ratios ranging from 1.12 to 1.25 ( Table 1 ). Because the variants were common, with risk allele frequencies ranging from 0.07 to 0.67, and the PAFs were high, ranging from 3.4 to 19.6 % , each exceeded the PAF of hereditary nonpolyposis colorectal cancer. Tenesa et al . (7) identied some of the same variants and an additional one on chromosome 11q23 with a PAF of 6.1 % . Carrying out a joint analysis by considering these low penetrance disease alleles to be shared in the population and assuming multiplicative epistatic interactions, the joint PAF was 52.0 % . Table 1 also shows the familial risks conferred by the variants, which are jointly only 1.05, far from the empirical familial risk of 2.5. e low familial risk conferred by the new variants is consistent with them being markers of rarer functional alleles.
Population attributable fractions for known colorectal cancer susceptibility genes are shown in Figure 1 . e estimated joint PAF of the high-risk genes is 3 % , dominated by mismatch repair genes and also including APC, MUTYH, LKB1, SMAD4, and others. For the moderate penetrance genes, a major contribution would be by CHEK2 I157T (4) , probably accounting for 4 % . e low penetrant variants account for 52 % .
e present calculations are based on published data on odds ratios and allele frequencies, both of which may vary according to the populations studied. Limited data are available on genotypic and epistatic interactions and they are di cult to deduce from data on markers (3) . Moreover, the GWA studies only considered main genetic e ects, which may be products of any unmeasured gene -environment and gene -gene interactions. All the above points warrant caution in the interpretation of the PAF. e data appear, nevertheless, compelling in indicating the remarkably high population impacts of the described loci compared to the " classical " high penetrance genes. e relatively small number of moderate penetrance genes may be due to the technical di culties in detecting them. ese variants would be expected to be rare with allele frequencies at or below 1 % ; these are not gauged by the GWA platforms that are built on HapMap polymorphisms with frequencies higher than 5 % . Moreover, the risks conferred by them would be too low to be detected in linkage studies, which is probably the reason for the limited success of the large international linkage consortia in breast and prostate cancers. ere has been some enthusiasm in using combinations of low-risk alleles in individual risk assessment (ref. (8) and the related correspondence). However, because the risks are small and the uncertainty for individuals is large, even the combinations of risk alleles tend to minimally improve the predictive power of the existing risk factors, such as family history. Even though new low-penetrance loci are likely to be identi ed and to contribute to familial relative risk, we predict that the more clinically relevant discoveries will be in the realm of moderate penetrance genes, some of which may in fact be the functional variants tagged by the low-penetrance markers now reported.
Adoption of a Sitting Position in Transnasal Gastroscopy: A New Approach
Chaohui Yu , MD, PhD To the Editor: Along with the development of narrow-diameter endoscopes, the technique of operating these endoscopes through the nose has become feasible. Unsedated transnasal esophagogastroduodenoscopy (OGD) clearly improves patients ' tolerance and comfort compared with conventional peroral OGD (1 -4) . However, sometimes patients cannot undergo transnasal or peroral OGD examination in the conventional (decumbent) position, as they have a severe cough without intermission while they are in that position.
erefore, we adopted a sitting position for such a patient, allowing us to perform a transnasal OGD and diagnose a case of esophageal stula.
A 45-year-old woman visited our hospital complaining of cough, expectoration, and hemoptysis of 4 months ' duration.
irty years earlier, she had undergone a neoplasty for esophagotracheal stula. We suggested that she undergo an upper gastrointestinal endoscopy; however, because she had a severe cough in the decumbent position, we could not complete the peroral OGD examination. We requested that she take a sitting position for the transnasal OGD. She remained in the sitting position throughout the entire process, while intently watching the screen of a video monitor and talking with us at times.
ere were no signi cant signs of discomfort such as severe cough, nausea, or dry vomiting. Her tension and fear were also reduced through our discussions and by watching the screen, and the operation was nished successfully. Transnasal OGD showed that there was an ori cium stula, approximately 4 mm in diameter, at the 2-o ' clock position in the esophagus ( Figure 1 ) and 35 cm from the right nostril. It was determined to be an esophageal stula.
Although narrow-diameter endoscopes have been on the market for about 10 years, and transnasal OGD has been certi ed as presenting distinct advantages over conventional peroral OGD (1,2) , its use remains rather limited. e reasons for its limited adoption may include the perception by endoscopists that transnasal OGD o ers no signi cant advantage over conventional peroral OGD and the absence of training in its use (5) . However, the use of transnasal OGD may become more extensive in the future. We need to confront the di culty of having some patients unable 
